Cerebrolysin vs Eloralintide
Side-by-side comparison of key properties, dosing, and research.
Cognitive EnhancementAnti-Aging & Longevity
CerebrolysinGLP-1 / Weight Loss Agonists
Eloralintide- Summary
- Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Half-Life
- Variable for the complex; individual peptide fractions: minutes to hours
- ~7 days (estimated, long-acting design)
- Admin Route
- IV, IM
- SubQ
- Research
- —
- —
- Typical Dose
- 5–10 mL
- Under investigation in Phase 1/2 trials
- Frequency
- Daily for 10–20 days
- Once weekly
- Key Benefits
- Promotes neurogenesis and synaptic plasticity
- Approved for stroke rehabilitation (accelerates recovery)
- Alzheimer's disease: slows progression and improves cognition
- Traumatic brain injury recovery
- Enhances memory and executive function
- Neuroprotection against oxidative stress and excitotoxicity
- Anti-amyloid and anti-tau effects
- Mood improvement and reduced anxiety
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Side Effects
- Generally well tolerated
- Mild nausea and dizziness (IV infusion)
- Headache at initiation
- Rare: agitation (usually at very high doses)
- +2 more
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Stacks With
- —
- —